Literature DB >> 22312021

Connectivity map analysis of nonsense-mediated decay-positive BMPR2-related hereditary pulmonary arterial hypertension provides insights into disease penetrance.

Charles Flynn1, Siyuan Zheng, Ling Yan, Lora Hedges, Bethany Womack, Josh Fessel, Joy Cogan, Eric Austin, James Loyd, James West, Zhongming Zhao, Rizwan Hamid.   

Abstract

The molecular mechanisms underlying the reduced penetrance seen in the nonsense-mediated decay-positive (NMD+) BMPR2 mutation-associated hereditary pulmonary arterial hypertension (HPAH) remain unknown. We reasoned that the cellular and genetic mechanisms behind this phenomenon could be uncovered by combining expression profiling with Connectivity Map (cMap) analysis. Cultured lymphocytes from 10 patients with HPAH and 10 matched familial control subjects, all with NMD+ BMPR2 mutations, were subjected to expression analysis. For each group, the expression data were combined before analysis. This generated a signature of 23 up-regulated and 12 down-regulated genes in patients with HPAH compared with control subjects (the "PAH penetrance signature"). Although gene set enrichment analysis of this signature was not uniquely informative, cMap analysis identified drugs with expression signatures similar to the PAH penetrance signature. Several of these drugs were predicted to influence reactive oxygen species (ROS) formation. This hypothesis was tested and confirmed in the same cells initially subjected to the expression analysis using quantitative biochemical detection of ROS concentration. We conclude that expression of the PAH penetrance signature represents an increased risk of developing clinical HPAH and that ROS formation may play a role in pathogenesis of HPAH. These results provide the first molecular insights into NMD+ BMPR2 related HPAH penetrance and highlight the potential utility of cMap analyses in pulmonary research.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22312021      PMCID: PMC3402799          DOI: 10.1165/rcmb.2011-0251OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  41 in total

1.  Excitation-contraction coupling in pulmonary vascular smooth muscle involves tyrosine kinase and Rho kinase.

Authors:  L J Janssen; H Lu-Chao; S Netherton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-04       Impact factor: 5.464

2.  The connectivity map.

Authors:  Stephen W Michnick
Journal:  Nat Chem Biol       Date:  2006-12       Impact factor: 15.040

3.  Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.

Authors:  Wai K P Wong; James A Knowles; Jane H Morse
Journal:  Am J Respir Cell Mol Biol       Date:  2005-07-07       Impact factor: 6.914

4.  Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension.

Authors:  Suparna M Chandra; Hedi Razavi; Jongmin Kim; Rani Agrawal; Ramendra K Kundu; Vinicio de Jesus Perez; Roham T Zamanian; Thomas Quertermous; Hyung J Chun
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-01-13       Impact factor: 8.311

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

Review 6.  Nonsense-mediated mRNA decay in Saccharomyces cerevisiae.

Authors:  C I González; A Bhattacharya; W Wang; S W Peltz
Journal:  Gene       Date:  2001-08-22       Impact factor: 3.688

7.  Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele.

Authors:  Rizwan Hamid; Joy D Cogan; Lora K Hedges; Eric Austin; John A Phillips; John H Newman; James E Loyd
Journal:  Hum Mutat       Date:  2009-04       Impact factor: 4.878

8.  Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension.

Authors:  Rajiv D Machado; Nung Rudarakanchana; Carl Atkinson; Julia A Flanagan; Rachel Harrison; Nicholas W Morrell; Richard C Trembath
Journal:  Hum Mol Genet       Date:  2003-10-28       Impact factor: 6.150

9.  Oxidative injury is a common consequence of BMPR2 mutations.

Authors:  Kirk L Lane; Megha Talati; Eric Austin; Anna R Hemnes; Jennifer A Johnson; Joshua P Fessel; Tom Blackwell; Ray L Mernaugh; Linda Robinson; Candice Fike; L Jackson Roberts; James West
Journal:  Pulm Circ       Date:  2011       Impact factor: 3.017

10.  Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1.

Authors:  Victoria C Foletta; Mei Ann Lim; Juliana Soosairajah; April P Kelly; Edouard G Stanley; Mark Shannon; Wei He; Supratik Das; Joan Massague; Ora Bernard; Juliana Soosairaiah
Journal:  J Cell Biol       Date:  2003-09-08       Impact factor: 10.539

View more
  9 in total

1.  Meta-analysis of blood genome-wide expression profiling studies in pulmonary arterial hypertension.

Authors:  Jason M Elinoff; Adrien J Mazer; Rongman Cai; Mengyun Lu; Grace Graninger; Bonnie Harper; Gabriela A Ferreyra; Junfeng Sun; Michael A Solomon; Robert L Danner
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-10-16       Impact factor: 5.464

2.  Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers.

Authors:  Mingxia Gu; Ning-Yi Shao; Silin Sa; Dan Li; Vittavat Termglinchan; Mohamed Ameen; Ioannis Karakikes; Gustavo Sosa; Fabian Grubert; Jaecheol Lee; Aiqin Cao; Shalina Taylor; Yu Ma; Zhixin Zhao; James Chappell; Rizwan Hamid; Eric D Austin; Joseph D Gold; Joseph C Wu; Michael P Snyder; Marlene Rabinovitch
Journal:  Cell Stem Cell       Date:  2016-12-22       Impact factor: 24.633

3.  Genotype-phenotype effects of Bmpr2 mutations on disease severity in mouse models of pulmonary hypertension.

Authors:  Andrea L Frump; Arunima Datta; Sampa Ghose; James West; Mark P de Caestecker
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

4.  Expression of mutant bone morphogenetic protein receptor II worsens pulmonary hypertension secondary to pulmonary fibrosis.

Authors:  Andrew J Bryant; Linda J Robinson; Christy S Moore; Thomas R Blackwell; Santhi Gladson; Niki L Penner; Ankita Burman; Lucas J McClellan; Vasiliy V Polosukhin; Harikrishna Tanjore; Melinda E McConaha; Linda A Gleaves; Megha A Talati; Anna R Hemnes; Joshua P Fessel; William E Lawson; Timothy S Blackwell; James D West
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

Review 5.  Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension.

Authors:  James West; Eric Austin; Joshua P Fessel; James Loyd; Rizwan Hamid
Journal:  Drug Discov Today       Date:  2014-05-02       Impact factor: 7.851

6.  Non-alcoholic fatty liver disease phosphoproteomics: A functional piece of the precision puzzle.

Authors:  Julia Wattacheril; Kristie L Rose; Salisha Hill; Christian Lanciault; Clark R Murray; Kay Washington; Brandon Williams; Wayne English; Matthew Spann; Ronald Clements; Naji Abumrad; Charles Robb Flynn
Journal:  Hepatol Res       Date:  2017-04-19       Impact factor: 4.288

Review 7.  Genetics and the molecular pathogenesis of pulmonary arterial hypertension.

Authors:  Dong Liu; Nicholas W Morrell
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

8.  Molecular Mechanisms of Mild and Severe Pneumonia: Insights from RNA Sequencing.

Authors:  Sai Huang; Cong Feng; Li Chen; Zhi Huang; Xuan Zhou; Bei Li; Li-Li Wang; Wei Chen; Fa-Qin Lv; Tan-Shi Li
Journal:  Med Sci Monit       Date:  2017-04-06

9.  Several genes involved in the JAK-STAT pathway may act as prognostic markers in pancreatic cancer identified by microarray data analysis.

Authors:  Chun Pang; Yuan Gu; Yuechao Ding; Chao Ma; Wei Yv; Qian Wang; Bo Meng
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.